Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F14%3A%230000170" target="_blank" >RIV/26475821:_____/14:#0000170 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/14:10271883 RIV/00669806:_____/14:10271883

Result on the web

<a href="http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1578&id=17234" target="_blank" >http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1578&id=17234</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1700/1578.17234" target="_blank" >10.1700/1578.17234</a>

Result language

angličtina

Original language name

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Original language description

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

EB - Genetics and molecular biology

OECD FORD branch

—

Project

<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Tumori

ISSN

0300-8916

e-ISSN

—

Volume of the periodical

100

Issue of the periodical within the volume

3

Country of publishing house

IT - ITALY

Number of pages

4

Pages from-to

70-73

UT code for WoS article

—

EID of the result in the Scopus database

—